文献速递细菌感染、耐药与抗菌药物医院感染防控

加拿大ICU抗菌药物耐药病原体:CANWARD 2007-2016研究

Antimicrobial-resistant pathogens in Canadian ICUs: results of the CANWARD 2007 to 2016 study.
PubMed 文献 · J Antimicrob Chemother · 2019-01-01

CANWARD监测研究分析了2007-2016年加拿大ICU分离的8130株病原体,发现呼吸道标本占58.2%。MRSA占金黄色葡萄球菌20.7%,CA-MRSA基因型流行率显著增加(P<0.001);产ESBL大肠埃希菌占10.1%,且随时间显著增加。

要点

  • ICU病原体以呼吸道标本为主(58.2%),金黄色葡萄球菌、铜绿假单胞菌和大肠埃希菌最常见。
  • MRSA对万古霉素、头孢吡普、利奈唑胺敏感率均为100%。
  • 碳青霉烯类、替加环素和哌拉西林/他唑巴坦对革兰阴性杆菌活性最高。

核心结论

  • 对革兰阴性杆菌最有效的药物是碳青霉烯类、替加环素和哌拉西林/他唑巴坦。
  • 对革兰阳性球菌最有效的药物是万古霉素、达托霉素和利奈唑胺。
  • ICU中CA-MRSA基因型和产ESBL大肠埃希菌的流行率随时间显著增加。

研究设计与样本

  • 2007至2016年加拿大三级医疗中心参与的CANWARD监测研究,共收集42938株细菌/真菌分离株,其中8130株(18.9%)来自ICU患者。
  • 药敏试验指南和MIC判读标准由CLSI定义。

主要发现

  • 8130株病原体中,58.2%来自呼吸道标本,36.3%来自血液,3.1%来自伤口,2.4%来自尿液。
  • ICU前五位病原体占所有分离株的55.4%,包括金黄色葡萄球菌(21.5%)、铜绿假单胞菌(10.6%)、大肠埃希菌(10.4%)、肺炎链球菌(6.5%)和肺炎克雷伯菌(6.4%)。
  • MRSA占金黄色葡萄球菌的20.7%,CA-MRSA基因型流行率随时间增加(P < 0.001)。
  • MRSA对万古霉素、头孢吡普、利奈唑胺的敏感率均为100%,对头孢洛林、达托霉素、替加环素的敏感率均为99.7%。
  • 大肠埃希菌对替加环素敏感率为100%,对美罗培南99.9%,对黏菌素99.7%,对哌拉西林/他唑巴坦94.2%;26.3%为MDR,10.1%产ESBL。

关键数值与推荐

  • 药敏判读采用CLSI标准和MIC折点。
  • CA-MRSA基因型流行率随时间增加,P < 0.001。
  • 大肠埃希菌中MDR占26.3%,产ESBL占10.1%。

临床怎么用

  • ICU经验性治疗革兰阴性杆菌感染可考虑碳青霉烯类、替加环素或哌拉西林/他唑巴坦。
  • 针对革兰阳性球菌,万古霉素、达托霉素和利奈唑胺保持高度活性。
  • 需关注ICU中CA-MRSA和产ESBL大肠埃希菌流行率上升的趋势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To describe the microbiology and antimicrobial resistance patterns of cultured samples acquired from Canadian ICUs. METHODS: From 2007 to 2016, tertiary care centres from across Canada submitted 42938 bacterial/fungal isolates as part of the CANWARD surveillance study. Of these, 8130 (18.9%) were from patients on ICUs. Susceptibility testing guidelines and MIC interpretive criteria were defined by CLSI. RESULTS: Of the 8130 pathogens collected in this study, 58.2%, 36.3%, 3.1% and 2.4% were from respiratory, blood, wound and urine specimens, respectively. The top five organisms collected from Canadian ICUs accounted for 55.4% of all isolates and included Staphylococcus aureus (21.5%), Pseudomonas aeruginosa (10.6%), Escherichia coli (10.4%), Streptococcus pneumoniae (6.5%) and Klebsiella pneumoniae (6.4%). MRSA accounted for 20.7% of S. aureus collected, with community-associated (CA) MRSA genotypes increasing in prevalence over time (P < 0.001). The highest susceptibility rates among MRSA were 100% for vancomycin, 100% for ceftobiprole, 100% for linezolid, 99.7% for ceftaroline, 99.7% for daptomycin and 99.7% for tigecycline. The highest susceptibility rates among E. coli were 100% for tigecycline, 99.9% for meropenem, 99.7% for colistin and 94.2% for piperacillin/tazobactam. MDR was identified in 26.3% of E. coli isolates, with 10.1% producing an ESBL. The highest susceptibility rates among P. aeruginosa were 97.5% for ceftolozane/tazobactam, 96.1% for amikacin, 94.7% for colistin and 93.3% for tobramycin. CONCLUSIONS: The most active agents against Gram-negative bacilli were the carbapenems, tigecycline and piperacillin/tazobactam. Against Gram-positive cocci, the most active agents were vancomycin, daptomycin and linezolid. The prevalence of CA-MRSA genotypes and ESBL-producing E. coli collected from ICUs increased significantly over time.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Denisuik AJ, Garbutt LA, Golden AR, et al. Antimicrobial-resistant pathogens in Canadian ICUs: results of the CANWARD 2007 to 2016 study. J Antimicrob Chemother. 2019. PMID: 30500898. doi:10.1093/jac/dky477

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。